Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

A Phase 0, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Assess Ketamine-induced Changes in ERP Biomarkers in Healthy Volunteers

This is a Phase 0, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to assess the changes in ERP Biomarkers in Healthy Volunteers before and after administration of a sub-anesthetic dose of ketamine. Primary objectives are to quantify the effect size of ketamine-induced changes on MMN from a duration-deviant auditory oddball ERP test and to quantify the variability of ketamine-induced changes on MMN from a duration-deviant auditory oddball ERP test.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Ketamine

Detailed Description

The effects of ketamine and similar compounds on brain function have become of significant interest to pharma companies in the past few years. These effects are often used as a model for the glutamatergic hypofunction hypothesis of schizophrenia and therefore drugs targeting schizophrenia are being trialed to reverse or block the effects of ketamine. Esketamine has been recently approved as a potent treatment for depression so many pharma companies are trying to leverage ketamine-like modulation of the NMDA receptors as novel targets for depression.

This heightened focus on NMDAr modulators has lead industry and academia to advance methods to measure these effects. Many studies have been performed using EEG and ERP techniques to measure the effect on brain function of ketamine administration but no study has been performed, to our knowledge, that has attempted to measure the variability and reproducibility of these effects. Furthermore, there is some evidence from the scientific literature and from unpublished results from industry-sponsored studies that ketamine may have a disordinal effect on various electrophysiologic measures, particularly the amplitude of the mismatch negativity (MMN) from an auditory oddball ERP test.

In this study we will run various EEG/ERP tests on participants during a placebo administration and during two ketamine administrations separated by washout periods. This will allow, for the first time, the evaluation of the test-retest variability of a range ERP/EEG measures under ketamine administration vs placebo. This may also allow us to test the hypothesis that ketamine has a disordinal effect on different subjects and this disordinality can be predicted from a baseline (placebo) measurement.

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • Marlton, New Jersey, United States, 08053
      • Hassman Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy male and female subjects 21-40 years of age, inclusive at Visit 1 (Screening).
2. Female subjects with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (e.g., oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the study and for 30 days after the last dose of ketamine.
3. Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.
4. Subject is judged to be in good health as determined by the investigator.
5. Body mass index (BMI ) between 18.5 and 30.0 (inclusive) at Visit 1 (Screening).
6. Ability to detect a 1000 and 2000 Hz tone at 40 dB in both ears, at Visit 1 (Screening).
7. Ability to tolerate the electrode cap for the duration of the testing session.

Exclusion Criteria:

1. Clinically significant alcohol or other substance abuse within the last 1 year, in the opinion of the investigator; or unable to abstain from alcoholic beverages during the course of the study.
2. Positive alcohol/drug screen for drugs of abuse (with the exception of a positive result considered by the investigator to be directly attributable to prescription medication approved for subject use) such as phencyclidine, benzodiazepines, opiates, cocaine, cannabinoids, amphetamines, and cotinine at any Visit.
3. Excessive caffeine use (defined as habitual consumption of > 400 mg caffeine per day [~ four 8 oz. cups brewed caffeinated coffee or tea, ~ ten 12 oz. cans caffeinated soda or ~ two "energy shot" drinks]), or unable to abstain from caffeine on Visits 2-4.
4. Use of products containing nicotine (tobacco or vaping products) 60 minutes prior to dosing on Visits 2-4.
5. Current or prior history (defined as in the past 6 months) of treatment with N-methyl-D-aspartate receptor (NMDAR) ligands including ketamine, amantadine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.
6. History of allergy, sensitivity, or intolerance to NMDAR ligands including ketamine, amantadine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.
7. Any impairment, activity, or situation that in the judgment of the investigator would prevent satisfactory completion of the study protocol.
8. History of significant psychiatric, neurologic (e.g. Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, Type I or Type II diabetes mellitus, or a history of seizures, epilepsy, or strokes), or cognitive disorders (e.g. bipolar, schizophrenia, psychosis), or current (within 12 months prior to screening) psychiatric or cognitive disorders such as major depression, suicidal ideation, dementia, or anxiety disorders).
9. Abnormal medical history, or concurrent conditions that, in the opinion of the investigator or sponsor designated medical monitor, would preclude safe study participation, or interfere with study procedures/assessments.
10. History of severe renal or hepatic impairment, in the opinion of the investigator or the sponsor medical monitor.
11. Known history of significant cardiovascular condition such as myocardial infarction, congestive heart failure, clinically significant arrhythmias, current uncontrolled cardiac arrhythmias, angina, acute ischemia.
12. Hypertension characterized by resting systolic blood pressure > 140 mmHg or resting diastolic > 90 mmHg or tachycardia defined as a resting HR ≥ 120 bpm or bradycardia defined as a resting HR of ≤ 50 bpm, at any Visit.
13. Hypotension with an abnormal supine blood pressure defined as SBP < 90 mmHg or DBP <60 mmHg at any Visit.
14. Orthostatic hypotension consisting of a SBP change of ≥ 30 mmHg or a DBP change of ≥ 20 mmHg at 3 minutes after standing from a supine position at any Visit.
15. Resting heart rate < 45 or > 95 beats per minute.
16. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at Visit 1 (Screening).
17. A history of additional risk factors for Torsade de Pointes (such as heart failure, hypokalaemia, or family history of Long QT Syndrome).
18. Current evidence of dysplasia or history of malignancy (including lymphoma and leukemia) in the last 5 years, with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
19. Human immunodeficiency virus (HIV) infection, hepatitis, or other ongoing infectious disease that the investigator considers clinically significant.
20. History of gastrointestinal disease or surgery (except simple appendectomy or hernia repair), which can influence the absorption of the study drug.
21. Evidence of an infection at the time of clinic admission, in the opinion of the investigator.
22. Received an investigational product or device within 30 days (or 5 half-lives, whichever is longer) of dosing.
23. Use of first generation, sedating H1 antihistamines or sedative-hypnotic medications within 1 week prior to dosing.
24. Poor venous access; or have donated or had a significant loss of blood or plasma within 8 weeks of dosing.
25. Known allergy to latex.
26. Prior adverse reaction to ketamine or esketamine.
27. Medical history, conditions, or situations that, in the opinion of the investigator, would preclude safe study participation, or interfere with study procedures/assessments.
28. In addition to these criteria, the investigator may discontinue subjects at any time based on his or her clinical judgment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1; Visit 2: Placebo - Placebo; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Ketamine	Drug: Ketamine; Ketamine IV administration
Experimental: Arm 2; Visit 2: Placebo - Ketamine; Visit 3: Placebo - Placebo; Visit 4: Placebo - Ketamine	Drug: Ketamine; Ketamine IV administration
Experimental: Arm 3; Visit 2: Placebo - Ketamine; Visit 3: Placebo - Ketamine; Visit 4: Placebo - Placebo	Drug: Ketamine; Ketamine IV administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ketamine-induced changes in Amplitude for parameters from the ERP tests.	Amplitude changes (in microvolts) for the following parameters from the ERP tests: 1. Passive, Duration-deviant, Oddball ERP a. MMN	Pre-intervention/Dosing

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ketamine-induced changes in Amplitude for parameters from the ERP tests.	Amplitude changes (in microvolts) for the following parameters from the ERP tests: Passive, Duration-deviant, Oddball ERPN100P3a; Active, Auditory Oddball ERPN100N200P3b	Pre-intervention/Dosing
Ketamine-induced changes in Latency for parameters from the ERP tests.	Latency changes (in milliseconds) for the following parameters from the ERP tests: Passive, Duration-deviant, Oddball ERPN100MMNP3a; Active, Auditory Oddball ERPN100N200P3b	Pre-intervention/Dosing
Ketamine-induced change in Task Accuracy from the behavioral response during the active, auditory oddball ERP test.	Change in Task Accuracy as a percentage of correct behavioral responses during the active, auditory oddball ERP test.	Pre-intervention/Dosing
Ketamine-induced change in Reaction Time from the behavioral response during the active, auditory oddball ERP test.	Change in Reaction Time for the correct behavioral responses measured in milliseconds during the active, auditory oddball ERP test.	Pre-intervention/Dosing
Ketamine-induced change in Evoked Power from the auditory steady-state response (ASSR) paradigm.	Change in Evoked Power measured in µv2/Hz from the ASSR paradigm.	Pre-intervention/Dosing
Ketamine-induced change in Inter-trial coherence (ITC) from the auditory steady-state response (ASSR) paradigm.	Inter-trial coherence (ITC) from the ASSR paradigm will be measured on a scale between 0 (no coherence) and 1 (maximum coherence). Outcome measure will be change in ITC.	Pre-intervention/Dosing
Ketamine-induced changes in Absolute Power for Pharmaco-EEG parameters per IPEG guidelines.	Changes in Absolute Power (measured in µv2/Hz) for the following Pharmaco-EEG parameters: Delta power; Theta power; Alpha power; Beta power; Gamma power; Total power	Pre-intervention/Dosing
Ketamine-induced changes in Relative Power for Pharmaco-EEG parameters per IPEG guidelines.	Relative Power for Pharmaco-EEG parameters will be measured on a scale from 0 (no power in frequency band) to 1 (all EEG power in that frequency band). Outcome measures will be changes in Relative Power for the following Pharmaco-EEG parameters: Delta power; Theta power; Alpha power; Beta power	Pre-intervention/Dosing
Ketamine-induced change in the Dominant Frequency for the Alpha frequency band per IPEG guidelines.	Dominant frequency will be measured in Hz in the frequency interval between 6.0 and < 12.5 Hz. Outcome measure will be change in the Dominant Frequency for the Alpha frequency band.	Pre-intervention/Dosing
Ketamine-induced changes in Slow Wave Index per IPEG guidelines.	Slow Wave Index (SWI) will be calculated as Alpha/(Delta+Theta), and will be measured as ratio. Outcome measure will be change in SWI.	Pre-intervention/Dosing
Ketamine-induced changes in Theta/Beta ratio per IPEG guidelines.	Theta/Beta (TBR) will be measured as ratio. Outcome measure will be change in TBR.	Pre-intervention/Dosing
Correlations between Ketamine blood concentration and Ketamine-induced changes in Amplitude for parameters from the ERP tests.	Correlations between ketamine blood concentration and amplitude changes (in microvolts) for the following parameters from the ERP tests: Passive, Duration-deviant, Oddball ERPa. MMN; Passive, Duration-deviant, Oddball ERPN100P3a; Active, Auditory Oddball ERPN100N200P3b	Pre-intervention/Dosing
Correlations between Ketamine blood concentration and Ketamine-induced changes in Latency for parameters from the ERP tests.	Correlations between ketamine blood concentration and latency changes (in milliseconds) for the following parameters from the ERP tests: Passive, Duration-deviant, Oddball ERPa. MMN; Passive, Duration-deviant, Oddball ERPN100P3a; Active, Auditory Oddball ERPN100N200P3b	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced change in Task Accuracy from the behavioral response during the active, auditory oddball ERP test.	Correlation between Ketamine blood concentration and change in Task Accuracy measured as a percentage of correct behavioral responses during the active, auditory oddball ERP test.	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced change in Reaction Time from the behavioral response during the active, auditory oddball ERP test.	Correlation between Ketamine blood concentration and change in Reaction Time for the correct behavioral responses measured in milliseconds during the active, auditory oddball ERP test.	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced change in Evoked Power from the auditory steady-state response (ASSR) paradigm.	Correlation between Ketamine blood concentration and change in Evoked Power measured in µv2/Hz from the ASSR paradigm.	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced change in Inter-trial coherence (ITC) from the auditory steady-state response (ASSR) paradigm.	Correlation between Ketamine blood concentration and change in Inter-trial coherence (ITC) from the ASSR paradigm. Change in ITC will be measured on a scale between 0 (no coherence) and 1 (maximum coherence).	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced changes in Absolute Power for Pharmaco-EEG parameters.	Correlation between Ketamine blood concentration and changes in Absolute Power (measured in µv2/Hz) for the following Pharmaco-EEG parameters: Delta power; Theta power; Alpha power; Beta power; Gamma power; Total power	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced changes in Relative Power for Pharmaco-EEG parameters.	Correlation between Ketamine blood concentration and changes in Relative Power for the following Pharmaco-EEG parameters: Delta power; Theta power; Alpha power; Beta power	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced change in the Dominant Frequency for the Alpha frequency band.	Correlation between Ketamine blood concentration and Dominant frequency for the Alpha frequency band measured in Hz in the frequency interval between 6.0 and < 12.5 Hz.	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced changes in Slow Wave Index.	Correlation between Ketamine blood concentration and changes Slow Wave Index (SWI) calculated as Alpha/(Delta+Theta) ratio.	Pre-intervention/Dosing
Correlation between Ketamine blood concentration and Ketamine-induced changes in Theta/Beta ratio.	Correlation between Ketamine blood concentration and changes in Theta/Beta ratio (TBR).	Pre-intervention/Dosing

Collaborators and Investigators

• Sponsor: ERP Biomarker Qualification Consortium
• Collaborators: Merck Sharp & Dohme LLC; Novartis; Takeda; H. Lundbeck A/S; Astellas Pharma Inc; Alkermes, Inc.; Sage Therapeutics; Anavex Life Sciences Corp.; Apex Innovative Sciences; COGNISION
• Investigators: Principal Investigator: Marco Cecchi, PhD, The ERP Biomarker Qualification Consortium

Study record dates

Study Major Dates

• Study Start (Actual): May 26, 2022
• Primary Completion (Actual): December 12, 2022
• Study Completion (Actual): December 12, 2022

Study Registration Dates

• First Submitted: May 28, 2021
• First Submitted That Met QC Criteria: June 15, 2021
• First Posted (Actual): June 16, 2021

Study Record Updates

• Last Update Posted (Estimate): February 20, 2023
• Last Update Submitted That Met QC Criteria: February 17, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: Ketamine; Electroencephalogram; EEG; P300; ERP; MMN; Event-related potential; Mismatch Negativity; N100; P3a; P3b
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Ketamine
• Other Study ID Numbers: EBS-B

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No